Mycobacterium ulcerans Disease

Manson's Tropical Diseases: Twenty-Third Edition

Volumn , Issue , 2013, Pages 519-531

  Junghanss, Thomas ^a   Johnson, Roch Christian ^b   Pluschke, Gerd ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF ABOMEY CALAVI   (Benin)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942932679     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-5101-2.00043-1     Document Type: Chapter

References (60)

1. Stinear TP, Seemann T, Pidot S, et al. Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res 2007, 17:192-200.
2. Stinear TP, Mve-Obiang A, Small PL, et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 2004, 101:1345-1349.
3. Doig KD, Holt KE, Fyfe JA, et al. On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics 2012, 13:258.
4. Käser M, Rondini S, Naegeli M, et al. Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans. BMC Evol Biol 2007, 7:177.
5. Qi W, Käser M, Röltgen K, et al. Genomic diversity and evolution of Mycobacterium ulcerans revealed by next-generation sequencing. PLoS Pathog 2009, 5:e1000580.
6. Röltgen K, Qi W, Ruf MT, et al. Single nucleotide polymorphism typing of Mycobacterium ulcerans reveals focal transmission of Buruli ulcer in a highly endemic region of Ghana. PLoS Negl Trop Dis 2010, 4:e751.
7. Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007, 13:1653-1660.
8. Johnson PD, Lavender CJ Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerg Infect Dis 2009, 15:614-615.
9. Quek TY, Athan E, Henry MJ, et al. Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis 2007, 13:1661-1666.
10. Lavender CJ, Fyfe JA, Azuolas J, et al. Risk of Buruli ulcer and detection of Mycobacterium ulcerans in mosquitoes in southeastern Australia. PLoS Negl Trop Dis 2011, 5:e1305.
11. Fyfe JA, Lavender CJ, Handasyde KA, et al. A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis 2010, 4:e791.
12. WHO Regional Office for Africa Buruli ulcer Online. Available. http://www.afro.who.int/en/clusters-a-programmes/dpc/neglected-tropical-diseases/programme-components/buruli-ulcer-elimination.html.
13. PNLLUB 2011. Programme National de Lutte contre la Lèpre et l'Ulcère de Buruli). Rapport Annu 2010, MSP/DNPS/PNLLUB:50.
14. Johnson RC, Sopoh GE, Barogui Y, et al. Surveillance system for Buruli ulcer in Benin: results after four years. Cahier Sante 2008, 18:9-13.
15. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999, 283:854-857.
16. Coutanceau E, Decalf J, Martino A, et al. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 2007, 204:1395-1403.
17. Hong H, Coutanceau E, Leclerc M, et al. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2008, 2:e325.
18. Ruf MT, Sopoh GE, Brun LV, et al. Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?. PLoS Negl Trop Dis 2011, 5:e1334.
19. Schütte D, Pluschke G Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther 2009, 9:187-200.
20. Schütte D, Um-Boock A, Mensah-Quainoo E, et al. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 2007, 1:e2.
21. Diaz D, Döbeli H, Yeboah-Manu D, et al. Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol 2006, 13:1314-1321.
22. Okenu DM, Ofielu LO, Easley KA, et al. Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic. Clin Diagn Lab Immunol 2004, 11:387-391.
23. MacCallum P, Tolhurst JC, Buckle G, et al. A new mycobacterial infection in man. J Pathol Bacteriol 1948, 60:93-122.
24. Clancey JK, Dodge OG, Lunn HF, et al. Mycobacterial skin ulcers in Uganda. Lancet 1961, 2:951-954.
25. Debacker M, Aguiar J, Steunou C, et al. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health 2004, 9:1297-1304.
26. Stienstra Y, van der Werf TS, Oosterom E, et al. Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes Immun 2006, 7:185-189.
27. WHO Buruli ulcer. Mycobacterium Ulcerans Infection. WHO/CDS/CPE/GBUI/2000.1 2000, World Health Organization, Geneva. K. Asiedu, R. Scherpbier, M. Raviglione (Eds.).
28. WHO Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). WHO/CDS/CPE/GBUI/2004.10 Online. Available, (Accessed Dec 2012). http://www.who.int/buruli/information/antibiotics/en.
29. O'Brien DP, Robson ME, Callan PP, et al. 'Paradoxical' immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 2009, 191:564-566.
30. Nienhuis WA, Stienstra Y, Abass KM, et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012, 54:519-526.
31. Ruf MT, Chauty A, Adeye A, et al. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?. PLoS Negl Trop Dis 2011, 5:e1252.
32. Beissner M, Piten E, Maman I, et al. Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy - a case report from Togo. PLoS Negl Trop Dis 2012, 6:e1747.
33. WHO Buruli ulcer. Diagnosis of Mycobacterium Ulcerans Disease. WHO/CDS/CPE/GBUI/2001.4 2001, World Health Organization, Geneva. http://www.who.int/buruli/information/publications/en/index.html, F. Portaels, P. Johnson, W.M. Meyers (Eds.).
34. Stienstra Y, van der Graaf WT, Asamoa K, et al. Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg 2002, 67:207-213.
35. Aujoulat I, Johnson C, Zinsou C, et al. Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin. Trop Med Int Health 2003, 8:750-759.
36. Meyers WM, Shelly WM, Connor DH Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg 1974, 23:924-929.
37. Gordon CL, Buntine JA, Hayman JA, et al. Spontaneous clearance of Mycobacterium ulcerans in a case of Buruli ulcer. PLoS Negl Trop Dis 2011, 5:e1290.
38. Revill WD, Morrow RH, Pike MC, et al. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 1973, 2:873-877.
39. Fehr H, Egger M, Senn I Cotrimoxazol in the treatment of Mycobacterium ulcerans infection (Buruli ulcer) in west Africa. Trop Doct 1994, 24:61-63.
40. Espey DK, Djomand G, Diomande I, et al. A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis 2002, 6:60-65.
41. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005, 49:3182-3186.
42. Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007, 51:4029-4035.
43. Etuaful S, Carbonnelle B, Grosset J, et al. Bactericidal activity of rifampicin and streptomycin treatment for early human M. ulcerans lesions. Report of the 6th WHO Advisory Group Meeting on Buruli Ulcer, 10-13 March 2003, WHO headquarters, Geneva, Switzerland 2003, 99-102. World Health Organization, Geneva. http://whqlibdoc.who.int/hq/2003/WHO_CDS_CPE_GBUI_2003.8.pdf.
44. Kanga JM, Kacou DE, Dion-Laine M, et al. Medical treatment of Buruli ulcer in Côte d'Ivoire. Report of the 6th WHO Advisory Group Meeting on Buruli Ulcer, 10-13 March 2003, WHO headquarters, Geneva, Switzerland 2003, 99-100. World Health Organization, Geneva. http://whqlibdoc.who.int/hq/2003/WHO_CDS_CPE_GBUI_2003.8.pdf.
45. Chauty A The role of antibiotics in the management of Buruli ulcer at the Pobe Center in Benin In: Report of the 7th WHO Advisory Group Meeting on Buruli Ulcer, 8-11 March 2004, WHO headquarters, Geneva, Switzerland. Report online. Available. http://whqlibdoc.who.int/hq/2004/WHO_CDS_CPE_GBUI_2004.9.pdf.
46. Phillips R, Etuaful S, Asiedu K, et al. Management of M. ulcerans oedematous disease In: Report of the 7th WHO Advisory Group Meeting on Buruli Ulcer, 8-11 March 2004, Geneva, Switzerland, p. 122. Online. Available. http://whqlibdoc.who.int/hq/2004/WHO_CDS_CPE_GBUI_2004.9.pdf.
47. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010, 375:664-672.
48. Sarfo FS, Phillips R, Asiedu K, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010, 54:3678-3685.
49. Chauty A, Ardant M-F, Marsollier L, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011, 52:94-96.
50. Marsollier L, Honoré N, Legras P, et al. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob Agents Chemother 2003, 47:1228-1232.
51. Junghanss T, Um Boock A, Vogel M, et al. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis 2009, 3:e380.
52. WHO Wound and lymphoedema management. WHO/HTM/NTD/GBUI/2010.1 2010, World Health Organization. http://whqlibdoc.who.int/publications/2010/9789241599139_eng.pdf, J.M. Macdonald, M.J. Geyer (Eds.).
53. Merritt RW, Walker ED, Small PLC, et al. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis 2010, 4:e911.
54. WHO Buruli Ulcer. Management of Mycobacterium ulcerans disease. A manual for health care providers. Buntine and Crofts (eds) 2001, World Health Organization. http://www.who.int/buruli/information/publications/en/index.html.
55. WHO Treatment of Mycobaterium ulcerans disease (Buruli ulcer): guidance for health workers 2012, World Health Organization. http://www.who.int/iris/bitstream/10665/77771/1/9789241503402_eng.pdf.
56. Schütte D, Um-Boock A, Mensah-Quainoo E, et al. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 2007, 1:e2.
57. WHO Buruli ulcer. Diagnosis of Mycobacterium Ulcerans Disease. WHO/CDS/CPE/GBUI/2001.4 2001, World Health Organization, Geneva. http://www.who.int/buruli/information/publications/en/index.html, F. Portaels, P. Johnson, W.M. Meyers (Eds.).
58. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010, 375:664-672.
59. WHO Buruli Ulcer. Management of Mycobacterium ulcerans disease. A manual for health care providers Buntine and Crofts (eds) 2001, World Health Organization. http://www.who.int/buruli/information/publications/en/index.html.
60. WHO Treatment of Mycobaterium ulcerans disease (Buruli ulcer): guidance for health workers 2012, World Health Organization. http://www.who.int/iris/bitstream/10665/77771/1/9789241503402_eng.pdf.